The updated Phase 1a data and investor call could drive near-term volatility. Traders should watch for the abstract details at KCRS on July 24 and management commentary on July 27. The ongoing Phase 1b and planned Phase 3 registrational study (2028) keep the catalyst path intact but distant.
Drugs in focus
KURA drug pipeline →cabozantinib
● Neutral Named in this press release- Impact
- Phase
- Approved
- Time to market
- Already approved and commercially marketed since 2012 (first approval for medullary thyroid cancer)
- Next catalyst
- None dated
What to watchCabozantinib is Exelixis's sole approved drug, generating ~$2.12B in 2025 U.S. net revenue (17% YoY growth). The stock's next catalyst is the zanzalintinib PDUFA (Dec 3, 2026), not cabozantinib. For Kura Oncology holders: Kura's darlifarnib+cabozantinib combo data (44% ORR in pretreated ccRCC) is about Kura's drug resensitizing tumors to cabozantinib, not about cabozantinib itself. Watch Exelixis for cabozantinib commercial trends and the zanzalintinib readout.
How the stock moved after the report
NEUTRAL VIEWSTOCK BELOW ENTRY AT T+60- T+0 · Jul 14 $11.24entry
- T+1 · 4mo ago +0.80%α +0.40% · $11.33
- T+5 · 4mo ago −4.98%α −3.69% · $10.68
- T+20 · 3mo ago −11.65%α −14.15% · $9.93
- T+60 · 6w ago −5.07%α −8.45% · $10.67
Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
Kura Oncology announced an oral presentation of updated Phase 1a data from its FIT-001 trial of darlifarnib plus cabozantinib in advanced ccRCC at the 2026 Kidney Cancer Research Summit. The data show long-term follow-up in heavily pretreated cabozantinib-naïve patients, supporting the combination's potential. A virtual investor call is scheduled for July 27, 2026, following the presentation.
Key Facts
- Oral presentation at 2026 KCRS on July 24, 2026, featuring updated Phase 1a data from FIT-001 trial of darlifarnib + cabozantinib in advanced ccRCC.
- Data are long-term follow-up in heavily pretreated, cabozantinib-naïve patients with refractory RCC.
- Global randomized Phase 1b dose-optimization portion of FIT-001 (darlifarnib + cabozantinib vs. cabozantinib alone) is ongoing.
- Registrational Phase 3 study planned for 2028.
- Virtual investor call on July 27, 2026 at 8:00 a.m. ET.
- Darlifarnib is a next-generation FTI designed to inhibit farnesylation of RHEB and suppress mTORC1 signaling.
Financial Impact
No financial data provided; no changes to revenue, guidance, or cash runway disclosed.
Risk Factors
- Updated Phase 1a data may not show meaningful differentiation vs. prior results.
- Phase 1b and planned Phase 3 are years away; no near-term registration catalyst.
- Competitive landscape for ccRCC combinations remains intense.
- Darlifarnib's broader combination strategy (PDAC with daraxonrasib) is early-stage and unvalidated.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3326716 |
Track record
29 reports on KURA
6 of 9 bullish or bearish reports moved the stock their way by T+60. Best: +52.28% at T+60 after the Jun 3, 2026 report. 10 of 14 went positive at some point.
Filters
- Nov 16, 2026today Insider Buy Bullish 5/10 Entry $7.15 Now $7.09 −0.84% settles Feb 16
- Nov 16, 2026today 144 Neutral 3/10 Entry $7.15 Now $7.09 −0.84% settles Feb 16
- Nov 16, 2026today SC 13G/A Neutral 3/10 Entry $7.15 Now $7.09 −0.84% settles Feb 16
- Nov 10, 20266d ago S-3ASR Neutral 4/10 Entry $7.73 Now $7.09 −8.28% settles Feb 9
- Nov 10, 20266d ago Press Release Neutral 5/10 Entry $7.73 Now $7.09 −8.28% settles Feb 9
- Nov 4, 202612d ago Press Release Neutral 4/10 Entry $7.61 Now $7.09 −6.83% settles Feb 2
- Sep 29, 20266w ago Insider Cluster Bearish 5/10 Entry $10.71 Now $7.09 +33.80% settles Dec 24
- Sep 29, 20266w ago Press Release Bullish 6/10 Entry $10.81 Now $7.09 −34.38% settles Dec 23
- Sep 9, 20269w ago 8-K Bullish 6/10 Entry $12.09 Now $7.09 −41.36% settles Dec 3
- Sep 8, 20269w ago 8-K Neutral 2/10 Entry $12.52 Now $7.09 −43.37% settles Dec 2
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers